secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001725160-26-000033
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis first patient dosed in Phase 3 ASPENOVA trial for azenosertib in Cyclin E1+ PROC
--------------------------------------------------------------------------------

- Phase 3 ASPENOVA compares azenosertib 400mg QD 5:2 to standard-of-care chemo in ~420 Cyclin E1+ platinum-resistant ovarian cancer patients.
- Trial designed as confirmatory study to support full approval, with DENALI Part 2 topline expected by year-end 2026 for accelerated approval path.
- 400mg QD 5:2 dose selected based on DENALI Part 2a interim analysis showing differentiated response rate over 300mg with comparable safety.
- Collaborators include GOG Foundation, ENGOT, and APGOT; trial identifier NCT07546500.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/0001725160-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/zntl-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer